Shikari® (S-ATD) Anti-Denosumab ELISA
DEN-QLS-PRO
Enzyme immunoassay for the qualitative determination of specific antibodies to denosumab (Prolia®) in human serum and plasma.
This kit has been especially developed for the qualitative determination of denosumab in serum and plasma samples.
The Matriks Biotek Antibody to denosumab (Prolia®) Enzyme-Linked-ImmunoSorbentAssay (ELISA) Kit is intended for the qualitative determination of antibodies to denosumab (Prolia®) in serum and plasma. It is for professional use only. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system.
Research Use Only (RUO)
For technical inquiry, IFU and other relevant documents please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 20 |
| Total Time (min) | 140 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | +/- |
| Spike Recovery (%) | - |
| Shelf Life (year) | 1 |
| Assay type | Qualitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| Safety Data Sheet (SDS) | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Nanoparticle and Macromolecular Transfer across the Human Placental Barrier | Download | |
| Rahman, Mohammed Tanjimur, et al. "Nanoparticle-mediated synergistic drug combination for treating bone metastasis." Journal of Controlled Release 357 (2023): 498-510. | Visit Link | |
| Peterlin, Anton AN, et al. "Rethinking Bacterial Osteolysis: Translational Evidence From a Porcine Model and Fracture‐Related Infections." APMIS 134.2 (2026): e70151. | Visit Link |
